Anavex Life Sciences Corp (AVXL)

[TTTav66]

CTAD update—In addition to the previously shared late breaking oral communication, Anavex and Ariana will also be presenting 2 gut microbiota focused posters:

P90: Gut Microbiota and Response to Blarcamesine (ANAVEX2- 73) in Alzheimer’s Disease Patients: Abundance of Lachnospiraceae and Enterobacteriaceae Families as Potential Biomarker of Response from a 2-Year Study Interim Clinical Data Analysis using KEM Artificial Intelligence

Mohammad AFSHAR (1), Coralie WILLIAMS (1), Frederic PARMENTIER (1), Adrien ETCHETO (1), Christopher MISSLING (2) - (1)Ariana Pharma, France, (2)Anavex, United States


P99: Levels of gut microbiota potentially regulated through anti-inflammatory effect identified as associated to response to Blarcamesine (ANAVEX2-73) in Alzheimer’s disease patients in 2-year Interim clinical data using KEM Artificial Intelligence analysis

Mohammad AFSHAR (1), Coralie WILLIAMS (1), Frederic PARMENTIER (1), Adrien ETCHETO (1), Christopher MISSLING (2) - (1)Ariana Pharma, France, (2)ANAVEX, United States


Previously shared presentation:
P11: Novel analytics framework for augmenting single-arm Phase 2a open label trials with RealWorld external control data: Application to the Blarcamesine (ANAVEX®2-73) study in Alzheimer’s disease matched with propensity corrected patients from Alzheimer’s Disease

Mohammad AFSHAR (1), Coralie WILLIAMS (1), Nanthara SRITHARAN (1), Frederic PARMENTIER (1), Federico GOODSAID (2), Christopher MISSLING (3) - (1)Ariana Pharma, France, (2)Regulatory Pathfinders, United States, (3)ANAVEX, United States

https://www.ctad-alzheimer.com/files/files/POSTER%20PRESENTATIONS.pdf